Okyo Pharma (OKYO)Director bought ~$35K

~$35K

Approx. value · 25K sh @ $1.40

10.9M

Holds after · shares reported

Traded

Jul 20, 2026

Filed

Aug 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 20, 2026 · this disclosureInsider · First insider buy since Sep 2023Director purchased ~$35K of OKYO shares in the open market

What came next

1. Jul 21, 2026Insider · 4 peopleInsiders: 4 purchases (~$73K)
2. Jul 22, 2026Insider · 5 insiders in a week, a first since 2022CEO purchased ~$23K of OKYO shares in the open market
3. Jul 27, 2026Insider · 6 insiders in a week, a first since 2022Officer purchased ~$5K of OKYO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Okyo Pharma

For Okyo Pharma, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OKYO page.

Other recent filings by Gabriele M Cerrone, Director

• SEC Form 4 at Okyo Pharma (OKYO)Aug 8, 2026

The full history of Gabriele M Cerrone, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Okyo Pharma

• SEC Form 4Aug 8, 2026
• SEC Form 4Aug 8, 2026
• SEC Form 4Aug 8, 2026
• SEC Form 4Aug 8, 2026
• SEC Form 4Aug 8, 2026
• SEC Form 4Aug 8, 2026

Everything OQRO holds on this company is on its OKYO page.